<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02868996</url>
  </required_header>
  <id_info>
    <org_study_id>DM199-2016-001</org_study_id>
    <nct_id>NCT02868996</nct_id>
  </id_info>
  <brief_title>An Open Label, Phase 1b, Ascending Dose Study of DM199</brief_title>
  <official_title>An Open Label, Phase 1b, Single CENTER, Ascending Dose Study TO ASSESS THE SAFETY AND TOLERABILITY of DM199 With a Comparative Pharmacokinetic Study of DM199 Administered Intravenously and a Bioavailability Assessment of Subcutaneous Administration of DM199 in Normal Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DiaMedica Therapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novotech (Australia) Pty Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>DiaMedica Therapeutics Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1B study to assess the safety, tolerability and pharmacokinetics of DM199 in&#xD;
      healthy volunteers. The study will be consist of two parts: Part A will focus on intravenous&#xD;
      dosing and Part B will directly compare intravenous dosing with subcutaneous dosing.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>30 days</time_frame>
    <description>Assessment of safety of intravenous dosing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration of DM199 in plasma</measure>
    <time_frame>3 days</time_frame>
    <description>Assess plasma drug levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of bradykinin in plasma</measure>
    <time_frame>3 days</time_frame>
    <description>Assess drug associated biomarkers (e.g. plasma bradykinin levels)</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Low dose (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recombinant human tissue kallikrein</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium low dose (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recombinant human tissue kallikrein</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium high dose (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recombinant human tissue kallikrein</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recombinant human tissue kallikrein</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subcutaneous (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recombinant human tissue kallikrein</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recombinant human tissue kallikrein</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant human tissue kallikrein</intervention_name>
    <description>Intravenous DM199</description>
    <arm_group_label>High dose (Part A)</arm_group_label>
    <arm_group_label>IV (Part B)</arm_group_label>
    <arm_group_label>Low dose (Part A)</arm_group_label>
    <arm_group_label>Medium high dose (Part A)</arm_group_label>
    <arm_group_label>Medium low dose (Part A)</arm_group_label>
    <arm_group_label>Subcutaneous (Part B)</arm_group_label>
    <other_name>DM199</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female between 18 and 50 years of age (inclusive);&#xD;
&#xD;
          2. Healthy with no clinically significant medical problems;&#xD;
&#xD;
          3. BMI between 18 to 30 kg/m2 with a weight between 50 to 100 kg (both inclusive);&#xD;
&#xD;
          4. No history of alcohol or drug abuse (Paracetamol, Barbiturates, Benzodiazepines,&#xD;
             Cocaine, Methadone, Amphetamines, Methamphetamines, Opiates, Phencyclidine,&#xD;
             Tetrahydrocannabinol (cannabis), Tricyclic Antidepressants). Subjects should be&#xD;
             enrolled only after passing the urine drug screen (positive test for paracetamol will&#xD;
             be allowed);&#xD;
&#xD;
          5. Non-smokers or light smokers (Less than 5 cigarettes per day) by history and planned&#xD;
             during the study;&#xD;
&#xD;
          6. No history of significant allergic diathesis such as urticaria, angioedema or&#xD;
             anaphylaxis;&#xD;
&#xD;
          7. Receiving no chronic medications that affect blood pressure control, the bradykinin or&#xD;
             angiotensin system including angiotensin-converting-enzyme inhibitors (ACEi) or&#xD;
             angiotensin receptor blockers (ARB);&#xD;
&#xD;
          8. Willing and able to sign written, informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any significant past or current cardiac, pulmonary, hepatic, renal or other medical&#xD;
             condition which in the opinion of the investigator would make participation of the&#xD;
             subject in this study medically unsafe or compromise the accuracy of assessment of&#xD;
             safety, pharmacokinetic and pharmacodynamic data of the study;&#xD;
&#xD;
          2. Subjects who have abnormal safety labs outside the local lab ranges will be excluded&#xD;
             at PI's discretion based on his/her assessment of clinical significance (can be&#xD;
             repeated once at screening at PI's discretion);&#xD;
&#xD;
          3. Subjects with past medical history of malignancy except basal cell or squamous cell&#xD;
             carcinoma of the skin who have had curative surgical treatment and at least 6 months&#xD;
             have elapsed since the procedure;&#xD;
&#xD;
          4. A value outside the specified range of 90 mm Hg - 140 mm Hg for systolic blood&#xD;
             pressure and 50 mm Hg - 90 mm Hg for diastolic blood pressure (both inclusive) at&#xD;
             screening (can be repeated once at screening as per PI's discretion);&#xD;
&#xD;
          5. Subjects using angiotensin-converting-enzyme inhibitors (ACEi) or angiotensin receptor&#xD;
             blockers (ARB) to control blood pressure;&#xD;
&#xD;
          6. History of clinically significant acute bacterial, viral, or fungal systemic&#xD;
             infections in the last 4 weeks prior to screening;&#xD;
&#xD;
          7. Clinical or laboratory evidence of an active infection at the time of screening;&#xD;
&#xD;
          8. Known alpha 1-antitrypsin deficiency (Î±1-antitrypsin deficiency);&#xD;
&#xD;
          9. Serological evidence of human immunodeficiency virus (HIV), hepatitis B surface&#xD;
             antigen (HBsAg), or anti-hepatitis C virus (Anti-HCV) at screening;&#xD;
&#xD;
         10. Vaccination within 3 months of screening for the study or requiring vaccination during&#xD;
             the study or within 3 months after completion of the study;&#xD;
&#xD;
         11. Females who are pregnant or nursing;&#xD;
&#xD;
         12. Females of childbearing potential (i.e., any woman who is not surgically sterile e.g.,&#xD;
             hysterectomy, bilateral oophorectomy or &gt;1-year postmenopause status confirmed by&#xD;
             follicle-stimulating hormone (FSH) levels as defined by established lab ranges) and&#xD;
             all men who, if participating in heterosexual sexual activity that could lead to&#xD;
             pregnancy are unable or unwilling to practice medically effective contraception during&#xD;
             the study. They should agree to use two reliable methods of contraception (e.g.,&#xD;
             double-barrier condom plus diaphragm, condom or diaphragm plus a stable dose of&#xD;
             hormonal contraception) throughout the study period and until 3 months after receiving&#xD;
             study drug. Women of childbearing potential will require compulsory pregnancy testing.&#xD;
             A negative pregnancy test (serum and urine) will be documented during screening and at&#xD;
             Day -1 respectively;&#xD;
&#xD;
         13. Participation in any other drug study within 8 weeks or 5 half-lives of the study&#xD;
             drug, whichever is longer;&#xD;
&#xD;
         14. Unable or unwilling to comply with the protocol requirements for study visits and&#xD;
             procedures;&#xD;
&#xD;
         15. Subjects who do not have good venous access for infusion of study drug or for blood&#xD;
             sampling;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Linear Clinical Research</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <link>
    <url>http://www.ijclinicaltrials.com/index.php/ijct/article/view/238/129</url>
    <description>Safety, tolerability and pharmacokinetic profile of recombinant human tissue kallikrein, DM199, after intravenous and subcutaneous administration in healthy volunteers</description>
  </link>
  <verification_date>December 2017</verification_date>
  <study_first_submitted>August 8, 2016</study_first_submitted>
  <study_first_submitted_qc>August 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2016</study_first_posted>
  <last_update_submitted>December 5, 2017</last_update_submitted>
  <last_update_submitted_qc>December 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kallikreins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

